Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epacadostat and Sirolimus in Advanced Malignancy
NCT03217669Phase 1Unknown
- Start
- Feb 2018
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of epacadostat in solid tumor (advanced stage) and non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events at 28 days. Status: unknown.
02
Drugs
epacadostat
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03217669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217669.